Investor Presentation on unaudited Financial Results for Quarter and Half Year Ended September 30, 2026

November 03, 2026 To To The Listing Department, The Corporate Relations Department, National Stock Exchange of India Limited BSE Limited NSE Symbol: VIJAYA BSE Scrip Code: 543350 Dear Sir/Madam, Sub: Investor Presentation for Q2 FY27 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation on Financial Results for quarter and half year ended September 30, 2026, which would be used in the Investors / Analysts earnings conference call scheduled to be held on Wednesday, November 04, 2026, at 11:00 A.M. (IST). Please take the information on record. Thanking you. Yours faithfully, For Vijaya Diagnostic Centre Limited Narasimha Raju K A Chief Financial Officer Encl.: As Above Q2 & H1 FY27 Earnings Presentation November 3, 2026 Q2 & H1 FY25 Earnings Presentation, November 07, 2024 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. Q2 FY27 & H1 FY27 Performance Snapshot Strategic Expansion Q2 FY27 Performance Snapshot Financial Performance Key Metrics 1.37 Mn 4.98 Mn INR 2,554 Mn Footfall Tests Revenue from Operations INR 1,128 Mn | 44.1% INR 595 Mn | 23.3% 168 92% EBITDA | EBITDA Margin % PAT | PAT Margin % Centres B2C Revenue % YOY Growth % Geographical Contribution Wellness Share% 5% 3% 26.7% 16.5% 14.5% 5% 14.5% Revenue Test Volume Footfall Growth % Growth % Growth % 37.8% 37.4% EBITDA PAT Hyderabad RoAPT Pune West Bengal Others Welness Share % Growth % Growth % H1 FY27 Performance Snapshot Financial Performance Key Metrics 2.61 Mn 9.57 Mn INR 4,864 Mn Footfall Tests Revenue from Operations INR 2,113 Mn | 43.4% INR 1,126 Mn | 23.1% 168 92% EBITDA | EBITDA Margin % PAT | PAT Margin % Centres B2C Revenue % YOY Growth % Geographical Contribution Wellness Share% 4% 3% 24.8% 16.5% 13.7% 6% 14.6% Revenue Test Volume Footfall Growth % Growth % Growth % 36.0% 37.5% EBITDA PAT Hyderabad RoAPT Pune West Bengal Others Welness Share % Growth % Growth % Management Commentary I am pleased to share that we have sustained our strong growth momentum during Q2 FY27, delivering 26.7% year-on- year revenue growth, supported by 16.5% volume growth. Our existing centres grew by approximately 20%, while newer centres continued to ramp up well. Our core markets maintained strong momentum, while Pune has been witnessing a meaningful turnaround with consistent double-digit growth since few quarters. We continue to see encouraging momentum in West Bengal, as our brand awareness strengthens. We are particularly pleased with the response in Tier-II markets such as Krishnanagar and Diamond Harbour. On the expansion front, we have commissioned 2 hubs and 7 spokes so far during FY27. Looking ahead, we expect to commission another 3 hubs & 7 spokes in H2 FY27, followed by 3 additional hubs in Q1 FY28, further strengthening our network and expanding our presence across key markets. During the quarter, we entered into Business Transfer Agreement to acquire Arya Wellness Centre in Guwahati, Assam. This marks our entry into the North-East region and is an important step towards expanding our geographical presence beyond our existing markets. We believe this acquisition provides us with a strong platform to establish our presence in Commenting on the Q2 FY27 & H1 FY27 results and future Guwahati and gradually explore further growth opportunities across the North-East, leveraging our expertise in business outlook, Ms. Suprita integrated diagnostics and operational excellence Reddy, MD & CEO at Vijaya Diagnostic Centre Ltd. said: We remain committed to strengthening our presence across key markets, investing in advanced technology and delivering high-quality diagnostic services to support sustainable long-term growth. Key Financial Highlights (INR Mn) Revenue from Operations EBITDA & EBITDA Margin % PAT & PAT Margin % 40.6% 42.7% 44.1% 39.9% 43.4% 21.5% 23.0% 23.3% 21.0% 23.1% 4,864 3,896 Financials 2,016 2,310 2,554 2,113 1,126 1,554 818 985 1,128 433 531 595 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Radiology vs. Pathology Breakdown % B2C Revenue % Wellness share % Radiology Pathology Revenue 62% 63% 63% 62% 63% 92% 92% 92% 92% 92% 14.4% 14.8% 14.5% 14.3% 14.6% 38% 37% 37% 38% 37% Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Key Operational Highlights Tests Performed (# in Mn) Footfalls (# in Mn) Tests / Footfalls (#) 2.61 9.57 3.70 2.30 8.22 3.67 3.64 1.37 4.28 4.59 4.98 1.20 1.24 3.57 3.58 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Revenue per Test (INR) Revenue per Footfall (INR) 513 1,860 1,865 1,862 1,685 1,696 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Consolidated Profit & Loss Statement (INR Mn) Particulars Q2 FY27 Q2 FY26 Y-o-Y Q1 FY27 Q-o-Q H1 FY27 H1 FY26 Y-o-Y Revenue from operations 2,553.9 2,015.6 26.7% 2,309.8 10.6% 4,863.7 3,896.1 24.8% Cost of materials consumed 282.6 243.2 16.2% 256.0 10.4% 538.6 457.3 17.8% Gross Profit 2,271.2 1,772.4 28.1% 2,053.9 10.6% 4,325.1 3,438.8 25.8% Gro [Showing first 8,000 characters — download PDF for full document]